CNADF saw its Momentum Indicator move above the 0 level on December 04, 2024. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator turned positive. In of the 15 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for CNADF just turned positive on December 06, 2024. Looking at past instances where CNADF's MACD turned positive, the stock continued to rise in of 7 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator for CNADF entered a downward trend on December 18, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (57.958). P/E Ratio (0.000) is within average values for comparable stocks, (89.727). CNADF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.947). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (19.472).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CNADF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNADF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Industry PharmaceuticalsOther
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
UTWY | 43.99 | -0.53 | -1.19% |
US Treasury 20 Year Bond ETF | |||
FKU | 38.13 | -0.83 | -2.14% |
First Trust United Kingdom AlphaDEX® ETF | |||
DFAX | 24.76 | -0.57 | -2.25% |
Dimensional World ex US Core Eq 2 ETF | |||
SCHY | 23.09 | -0.55 | -2.33% |
Schwab International Dividend Equity ETF | |||
SDG | 72.41 | -1.81 | -2.44% |
iShares MSCI Global Sust Dev Goals ETF |
A.I.dvisor indicates that over the last year, CNADF has been loosely correlated with BJTRF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CNADF jumps, then BJTRF could also see price increases.
Ticker / NAME | Correlation To CNADF | 1D Price Change % | ||
---|---|---|---|---|
CNADF | 100% | N/A | ||
BJTRF - CNADF | 61% Loosely correlated | N/A | ||
STEK - CNADF | 26% Poorly correlated | -2.96% | ||
PLSH - CNADF | 21% Poorly correlated | N/A | ||
HLN - CNADF | 15% Poorly correlated | -2.02% | ||
DHBUF - CNADF | 7% Poorly correlated | +14.09% | ||
More |
Ticker / NAME | Correlation To CNADF | 1D Price Change % |
---|---|---|
CNADF | 100% | N/A |
Pharmaceuticals category (308 stocks) | -3% Poorly correlated | -1.36% |
Pharmaceuticals: Other category (226 stocks) | -9% Poorly correlated | -1.31% |